|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:The_Upjohn_Company
|
|
gptkbp:activities
|
serotonin receptor agonist
|
|
gptkbp:approves
|
gptkb:1986
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:brand
|
Buspar
|
|
gptkbp:contraindication
|
concurrent use of monoamine oxidase inhibitors
hypersensitivity to buspirone
|
|
gptkbp:developed_by
|
gptkb:W._R._Grace_and_Company
|
|
gptkbp:dosage_form
|
5 mg tablet
10 mg tablet
15 mg tablet
30 mg tablet
|
|
gptkbp:duration
|
long-term use possible
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Buspirone
|
|
gptkbp:ingredients
|
C21 H31 N5 O2
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_affected_by
|
gptkb:theorem
|
|
gptkbp:is_available_on
|
tablets
|
|
gptkbp:is_effective_against
|
gptkb:post-traumatic_stress_disorder
social anxiety disorder
obsessive-compulsive disorder
panic disorder
|
|
gptkbp:is_used_for
|
treatment of anxiety disorders
|
|
gptkbp:lifespan
|
2 to 3 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:premiered_on
|
1 to 2 weeks
|
|
gptkbp:release_region
|
gptkb:government_agency
gptkb:Australia
gptkb:Brazil
gptkb:India
gptkb:Japan
gptkb:Monarch
gptkb:South_Africa
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
excitement
nervousness
|
|
gptkbp:suitable_for
|
pregnant women
breastfeeding women
|
|
gptkbp:type_of
|
332-24-1
|
|
gptkbp:venomous
|
gptkb:theorem
|